A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer

Abstract

BackgroundTo date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.Methodology/Principal FindingsUsing microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression.ConclusionsOur observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

“…Although it has been in argument and discussion on reference strategies for normalizing circulating miRNAs, there is still no consensus (Ma et al, 2012). 5s rRNA, U6 snRNA, and miR‐16 are frequently used as internal normalization controls (Luo et al., 2009; Pineles et al, 2007; Zhao et al., 2010). In this study, U6 snRNA showed low abundance in the plasma samples.…”

The Plasma DNA Concentration as a Potential Breast Cancer Screening Marker

“…The plasma DNA concentration should be a marker for breast cancer screening that was easily accessible and noninvasive [16]. In addition, high sensitivity and specificity of the plasma DNA with fluorometric method provide a diagnostic advantage in screening.…”

Genomic and Epigenomic Cross-talks in the Regulatory Landscape of miRNAs in Breast Cancer

“…As serum and other body fluids contain ribonucleases, miRNAs are thought to be shielded from degradation by being packed in lipid vesicles, in complexes with RNA-binding proteins, or both (115). In a pilot study of circulating miRNAs as potential biomarkers for early-stage breast cancer, 48 serum miRNAs were found to be differentially expressed in patients when compared with controls (116). Of these, 22 were upregulated and 26 were downregulated.…”